Anti-cldn18.2 antibody and uses thereof

The anti-CLDN18.2 antibody addresses the need for improved gastric cancer treatments by inducing targeted cell killing through ADCC and CDC, enhancing therapeutic efficacy with reduced toxicity.

AU2018447127B2Pending Publication Date: 2026-07-23SHANGHAI GENBASE BIOTECH CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
AU · AU
Patent Type
Applications
Current Assignee / Owner
SHANGHAI GENBASE BIOTECH CO LTD
Filing Date
2018-10-22
Publication Date
2026-07-23

AI Technical Summary

Technical Problem

Current treatments for gastric cancer lack effective therapeutic targets, with existing drugs like HER2 and PD-1 antibodies showing limited efficacy, and there is a need for more specific and less toxic antibodies targeting CLDN18.2 for improved cancer immunotherapy.

Method used

Development of an anti-CLDN18.2 antibody or antigen-binding fragments with specific CDR sequences that induce ADCC and CDC, providing high affinity and specificity for CLDN18.2 expression, while minimizing toxicity and side effects.

Benefits of technology

The anti-CLDN18.2 antibody effectively kills tumor cells expressing CLDN18.2 through ADCC and CDC, offering a promising treatment option with enhanced clinical efficacy and reduced side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000001_0000
    Figure 00000001_0000
  • Figure 00000098_0000
    Figure 00000098_0000
  • Figure 00000099_0000
    Figure 00000099_0000
Patent Text Reader

Abstract

Provided are an anti-CLDN18.2 antibody or an antigen binding fragment thereof, a nucleic acid molecule encoding the antibody, and an immunoconjugate comprising same, a bispecific molecule, a chimeric antigen receptor and a pharmaceutical composition. The antibody or antigen binding fragment thereof is used for preventing and / or treating tumors.
Need to check novelty before this filing date? Find Prior Art